Comparing new treatments for arthritis of the spine or joints
Part of Bones, joints & muscles, Skin clinical trials.
This study looks at how well different newer medications work for people with axial spondyloarthritis or psoriatic arthritis. It focuses on those just starting treatment with bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with axial spondyloarthritis (a type of arthritis affecting the spine) or psoriatic arthritis (arthritis linked to psoriasis).
- You are 18 years old or older.
- You have just started (within the past month) a new treatment for your arthritis that is one of these medications: bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor.
- You are not currently taking part in another clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people recently diagnosed with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine). It tests whether a standardized global review and education program can help patients better understand and manage their condition.
This study tests whether the medicine upadacitinib (a pill that reduces inflammation) can reduce the number of acute uveitis flare-ups (eye inflammation) in people with axial spondyloarthritis (a type of arthritis affecting the spine). It may help prevent these painful eye episodes if you have them alongside your arthritis.
This study compares two newer medicines (an IL-17 inhibitor and a JAK inhibitor) for people with axial spondyloarthritis whose previous TNF inhibitor did not work or caused side effects. The goal is to see which one works better for controlling symptoms.
This trial tests whether bimekizumab is better than adalimumab at reducing chest wall pain in people with active axial spondyloarthritis who haven't responded to NSAIDs. It aims to find a more effective treatment option for this specific symptom.
This study looks at whether giving bimekizumab in different ways is safe and how it moves through the body over time. It is for adults with active psoriatic arthritis or axial spondyloarthritis who may benefit from bimekizumab treatment.
This trial tests a new oral medication that may reduce inflammation and improve symptoms in people with axial spondyloarthritis. It is in early phases, meaning the drug is still being studied for safety and effectiveness.
Hear when a new Axial Spondylarthritis (axSpA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.